Energizer's strong Q3 performance lifts outlook, driven by pricing, tariff mitigation, and production credits.
Lowering the recommended age for colorectal cancer screening has led to a significant rise in screening rates among US adults aged 45 to 49, with early-stage diagnoses nearly doubling.
Energizer's strong Q3 performance lifts outlook, driven by pricing, tariff mitigation, and production credits.
Lowering the recommended age for colorectal cancer screening has led to a significant rise in screening rates among US adults aged 45 to 49, with early-stage diagnoses nearly doubling.